Solve with reason

Reading File

Finding Sources

Reading File

Answer: E. Partial Agonism

The correct answer is E — Partial agonism.

The Question

A patient on haloperidol (a typical antipsychotic / full D2 antagonist) develops bradykinesia, tremor, and cogwheel rigidity — classic extrapyramidal side effects (EPS). He is switched to aripiprazole, which causes fewer EPS. Why?

Reasoning

The key lies in aripiprazole's unique receptor pharmacology at the D2 dopamine receptor.

Haloperidol → Full D2 Antagonist

Haloperidol blocks D2 receptors completely (intrinsic activity = 0). In the nigrostriatal pathway, dopamine normally suppresses involuntary movement. Full D2 blockade eliminates this dopaminergic tone → EPS (parkinsonism, tremor, cogwheeling, bradykinesia).

Aripiprazole → Partial D2 Agonist

Aripiprazole has intrinsic activity between 0 and 1 at D2 receptors. It acts as a "dopamine stabilizer":

Where dopamine is excessive (mesolimbic pathway → psychosis): aripiprazole occupies D2 receptors and transmits less signal than full dopamine → functional antagonism → antipsychotic effect
Where dopamine is low (nigrostriatal pathway → movement control): aripiprazole still provides some agonist stimulation → preserves nigrostriatal tone → far fewer EPS

"As a partial D2 agonist, aripiprazole offers the putative advantage of stabilizing the dopamine neurotransmitter system by decreasing the amount of signaling when there is excessive ligand... and by increasing the signal when there is reduced activity (by acting as an agonist)." — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

"Overactive dopaminergic pathways tend to be inhibited by aripiprazole, whereas underactive pathways are stimulated. This might explain the ability of aripiprazole to improve symptoms of schizophrenia, with a small risk of causing extrapyramidal adverse effects." — Lippincott Illustrated Reviews: Pharmacology

Why the Other Options Are Wrong

Option	Why incorrect
A. Agonism	Aripiprazole is not a full agonist — full agonism would worsen psychosis
B. Antagonism	Simple antagonism (like haloperidol) is what causes EPS — not what reduces it
C. Inverse agonism	Inverse agonists produce below-baseline receptor activity, which would worsen movement side effects
D. Irreversible antagonism	Irreversible blockade would cause permanent full D2 blockade — worse EPS, not less
F. Reversible antagonism	Still full antagonism at D2 → still causes EPS (haloperidol itself is a reversible competitive antagonist)

Summary

Aripiprazole's partial agonist activity at D2 receptors means it provides just enough nigrostriatal dopaminergic tone to avoid the parkinsonian EPS that full antagonists like haloperidol produce, while still blocking excessive mesolimbic dopamine activity responsible for psychosis. This "dopamine system stabilizer" property is the mechanistic basis for its reduced EPS profile.

Also explain the discussed topic

Finding Sources

Reading File

Loading Image

Drug-Receptor Interactions: The Full Topic Explained

The question tests your understanding of drug-receptor pharmacodynamics — specifically the spectrum of receptor interactions. Here is a complete explanation.

1. Core Concepts: Affinity vs. Intrinsic Activity

Every drug that acts at a receptor has two independent properties:

Property	Definition
Affinity	How tightly the drug binds to the receptor
Intrinsic activity (efficacy)	How much the drug activates the receptor after binding (0 = none, 1 = full)

Affinity gets you to the receptor. Intrinsic activity determines what happens next.

2. The Agonist Spectrum

Full agonist, partial agonist, and inverse agonist receptor activity curves

Lippincott Illustrated Reviews: Pharmacology — Receptor activity vs. log drug concentration

A. Full Agonist (Intrinsic activity = 1)

Binds AND fully activates the receptor
Produces the same maximum response (Emax) as the endogenous ligand
Example: Dopamine at D2 receptors; morphine at μ-opioid receptors

B. Partial Agonist (0 < Intrinsic activity < 1)

Binds the receptor but produces less than maximal activation, even when all receptors are occupied
Cannot reach the same Emax as a full agonist, regardless of dose
Dual character — acts as an agonist OR antagonist depending on context:

"A partial agonist can function both as an agonist or antagonist based on the presence or absence of the endogenous ligand." — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

In the absence of endogenous ligand → acts as an agonist (provides some signal)
In the presence of excess endogenous ligand → acts as a functional antagonist (displaces it and delivers less signal)

Example: Aripiprazole at D2 receptors; buprenorphine at μ-opioid receptors

C. Inverse Agonist (Intrinsic activity < 0)

Some receptors have constitutive (baseline) activity even without any drug
Inverse agonists bind and suppress receptor activity below baseline — they stabilize the inactive receptor conformation
Opposite pharmacological effect to agonists
Example: certain antihistamines at H1 receptors

D. Silent Antagonist (Intrinsic activity = 0)

Binds with high affinity but produces zero activation
Does not affect receptor activity alone, but blocks agonists from binding
Two subtypes:
- Competitive (reversible): Can be overcome by increasing agonist concentration; shifts dose-response curve rightward (↑EC50), Emax preserved. Example: haloperidol, naloxone
- Irreversible: Binds covalently or with very high affinity; cannot be overcome; permanently reduces Emax

3. Partial Agonism in Detail: The Two-Face Mechanism

Effects of partial agonist displacing full agonist

Lippincott — When partial agonist concentration rises, it displaces full agonist; total response settles at the partial agonist's ceiling

This is the key insight:

At low dopamine states → partial agonist provides some stimulation → agonist behavior
At high dopamine states → partial agonist competes with and displaces dopamine, transmitting less signal → functional antagonist behavior

This context-dependent behavior is what makes partial agonists so clinically valuable as "stabilizers."

4. Receptor Conformation: The Molecular Basis

Full agonist vs antagonist vs D2 partial agonist G-protein coupling

Stahl's Essential Psychopharmacology — Different receptor conformations produced by full agonist (large arrow = full G-protein signal), antagonist (no G coupling), and partial agonist (small arrow = reduced G-protein signal)

Each drug stabilizes a different receptor conformation:

Full agonist → fully open conformation → maximum G-protein coupling → maximum intracellular signal
Antagonist → closed/locked conformation → no G-protein coupling → no signal
Partial agonist → intermediate conformation → partial G-protein coupling → reduced signal

5. Applied to Schizophrenia: The Four Dopamine Pathways

This is why it all matters clinically:

Pathway	Dopamine State in Schizophrenia	Effect of Full Antagonist (Haloperidol)	Effect of Partial Agonist (Aripiprazole)
Mesolimbic (reward/psychosis)	↑↑ Excess	Blocks → treats positive symptoms ✓	Displaces excess dopamine → functional antagonist → treats positive symptoms ✓
Mesocortical (cognition/negative symptoms)	↓↓ Deficit	Blocks further → worsens negative/cognitive symptoms ✗	Provides some agonism → improves negative/cognitive symptoms ✓
Nigrostriatal (movement)	Normal	Full blockade → EPS (tremor, rigidity, bradykinesia) ✗	Small agonism preserves movement tone → minimal EPS ✓
Tuberoinfundibular (prolactin)	Normal	Full blockade → ↑ prolactin → galactorrhea ✗	Partial agonism → minimal prolactin elevation ✓

"Partial agonists are also proposed to have reduced liability for extrapyramidal symptoms (EPS) and hyperprolactinemia when excessive dopamine receptor blockade occurs in the nigrostriatal and tuberoinfundibular pathways." — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

6. Where Aripiprazole Sits on the Spectrum

A critical nuance from Stahl's Essential Psychopharmacology:

"The D2 partial agonists for the treatment of psychosis are 'almost' antagonists with just a whiff of intrinsic agonist activity."

Aripiprazole sits very close to the antagonist end of the agonist spectrum — just enough agonism to preserve nigrostriatal tone and avoid EPS, but close enough to antagonism to block hyperdopaminergic mesolimbic activity (positive symptoms). This precise positioning is what distinguishes antipsychotic partial agonists from dopamine partial agonists used in Parkinson's disease (which sit near the full-agonist end).

Summary Table

Drug Type	Intrinsic Activity	In Absence of Ligand	In Excess Ligand	Clinical Use
Full agonist	= 1	Full activation	Full activation	Replace/mimic endogenous ligand
Partial agonist	0 < x < 1	Partial activation	Functional antagonist	"Stabilizer" — aripiprazole, buprenorphine
Silent antagonist	= 0	No effect	Blocks agonist	Most classic drugs — haloperidol, naloxone
Inverse agonist	< 0	Suppresses baseline	Suppresses further	Reduce constitutive receptor activity

This is a shared conversation. Sign in to Orris to start your own chat.